Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz PharmaceuticalsFRA:J7Z +0.72%74 EV-to-EBIT is 20.22 as of Sep. 03, 2026, which is 13% above its 10-year median of 17.93. GuruFocus rates FRA:J7Z with a GF Score™ of 74/100 and a GF Value™ of €130.30 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 365 Biotechnology companies, Jazz Pharmaceuticals ranks worse than 56.44% on this metric.
Jazz Pharmaceuticals (FRA:J7Z) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jazz Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was €15,507 Mil.
Jazz Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €775 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals EV-to-EBIT Related Terms
Jazz Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J7Z vs ASND, BBIO, EXEL: EV-to-EBIT Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's EV-to-EBIT falls into.
Jazz Pharmaceuticals's current Enterprise Value is €15,658 Mil.
Jazz Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €775 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (FRA:J7Z) has a EV-to-EBIT of 20.22 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jazz Pharmaceuticals and its competitors. This is 13% above median its historical median of 17.93. According to the industry distribution chart, Jazz Pharmaceuticals ranks #206 out of 365 companies in the Biotechnology industry, placing it in the top 56.4%.
Is Jazz Pharmaceuticals' EV-to-EBIT too high?
Jazz Pharmaceuticals' current EV-to-EBIT of 20.22 is 13% above median its 10-year median of 17.93. The Biotechnology industry median EV-to-EBIT is 15.79. Jazz Pharmaceuticals' value of 20.22 is 28.1% above this industry median. Based on the distribution chart, Jazz Pharmaceuticals ranks #206 out of 365 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' EV-to-EBIT compare to ASND and BBIO?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #206 out of 365 companies for EV-to-EBIT. This places Jazz Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.79. Jazz Pharmaceuticals' value of 20.22 is 28.1% above this benchmark. While the company's 10-year median is 17.93 vs. the industry median of 15.79, Jazz Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.79, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jazz Pharmaceuticals's current EV-to-EBIT of 20.22 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current EV-to-EBIT is 20.22, which is 13% above median its own 10-year median of 17.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.30, compared to a current price of €211.00 — trading 61.9% above its estimated fair value. The current EV-to-EBIT is 20.22, which is 13% above median its 10-year median of 17.93 and 28.1% above the Biotechnology industry median of 15.79. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current EV-to-EBIT is 20.22 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €211.00 is trading 61.9% above its estimated GF Value™ of €130.30.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:J7Z:
EV-to-EBIT: 20.22 (13% above median its 10-year median of 17.93)
GF Value™: €130.30 vs. price of €211.00 (61.9% above fair value)
Industry Position: 28.1% above the Biotechnology median (#206 of 365)
No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score
Get the complete analysis for FRA:J7Z
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J7Z has been successfully added to your 
